Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

NCT00698568 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

7460

Enrollment

INDUSTRY

Sponsor class

Conditions

Prophylaxis for Herpes Simplex

Interventions

BIOLOGICAL: Herpes simplex candidate vaccine- adjuvanted GSK 208141
BIOLOGICAL: Placebo

Sponsor

GlaxoSmithKline